Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma.

JCO precision oncology - 1 Jan 2021

Chui M Herman, Chang Jason C, Zhang Yanming, Zehir Ahmet, Schram Alison M, Konner Jason, Drilon Alexander E, Da Cruz Paula Arnaud, Weigelt Britta, Grisham Rachel N

Abstract excerpt

Low-grade serous carcinoma (LGSC) is a rare type of ovarian cancer, which commonly arises from serous borderline tumor (SBT) and is characterized by frequent activating mutations in the mitogen-activated protein kinase pathway, including BRAF. The BRAF V600E mutation is associated with improved prognosis in SBT and LGSC, and responses to BRAF inhibitor therapy have been reported. We sought to characterize the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Gene Rearrangement

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to In Situ Hybridization, Fluorescence

Share to Mutation

Share to Neoplasm Grading

Share to Ovarian Neoplasms

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 34568720
DOI: 10.1200/PO.21.00055
PMCID: PMC8457847

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma.PMID 34568720Read ↗

The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.Semantic proximity Read ↗

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.Semantic proximity Read ↗

MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma.Semantic proximity Read ↗

Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.Semantic proximity Read ↗

Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.Semantic proximity Read ↗

Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.Semantic proximity Read ↗

The molecular pathology of ovarian serous borderline tumors.Semantic proximity Read ↗

The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.Semantic proximity Read ↗

Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.Semantic proximity Read ↗

Integrated genomic and histopathological analysis of low grade serous ovarian carcinoma identifies clinically distinct disease subtypesSemantic proximity Read ↗

The highs and lows of serous ovarian cancer.Semantic proximity Read ↗

Low‐grade serous carcinomas of the ovary contain very few point mutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.